Summary
The pharmacokinetics of a single oral dose of 20 mg (+)-, (-)- and racemic homochlorcyclizine (HCZ) have been studied in humans. The formation of the quarternary ammonium-linked glucuronide was an important metabolic pathway, and the metabolic process was enantioselective as a result of differing urinary excretion rates of (+)-, (-)- and racemic glucuronide.
There were significant differences between (+)-, (-) and racemic HCZ in AUC (0-14 h) and plasma protein binding, but all HCZ enantiomers were slowly absorbed and eliminated (elimination half-lives about 11 h).
The results shows help to establish a more efficient dosage regimen for HCZ therapy.
Similar content being viewed by others
References
Williams K, Lee E (1985) Importance of drug enantiomers in clinical pharmacology. Drugs 30:333–354
Jamali F, Mehvar R, Pasutto FM (1989) Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 78: 695–715
Lee EJD, Williams KM (1990) Chirality: clinical pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 18: 339–345
The Welfare Ministry of Japan (ed) (1991) Japanese Pharmacopeia XII
Tsutsumi J, Fujita T (1970) Determination of diphenylpyraline and hez in blood. Yakuzaigaku 30:258–260
Nishikata M, Nakai A, Fushida H, Miyake K, Arita T, Kitagawa S, Kunitomo M, Iseki K, Miyazaki K (1992) Method for optical resolution of racemic homochlorcyclizine and comparison of optical isomers in antihistamine activity and pharmacokinetics. Chem Pharm Bull 40:1341–1342
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879–885
Witiak DT, Lewis NJ (1978) Absorption, distribution, metabolism, and elimination of antihistamines. In: Silva MR (ed) Handbook of experimental pharmacology XVIII/2. Histamine II and anti-histaminics. Springer, Berlin Heidelberg New York
Paton DM, Webster DR (1985) Clinical pharmacokinetics of H1receptor antagonists (the antihistamines). Clin Pharmacokinet 10:477–497
Kuntzman R, Klutch A, Tsai I, Burns JJ (1965) Physiological distribution and metabolic inactivation of chlorcyclizine and cyclizine. J Pharmcol Exp Ther 149:29–35
Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJA (1975) Human metabolism of cyproheptadine. Drug Metab Dispos 3:189–197
Hucker HC, Stauffer SC, Balletto AJ, White SD, Zacchei AG, Arison BH (1978) Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Drug Metab Dispos 6: 659–672
Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 42:535–541
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nishikata, M., Nomura, A., Iseki, K. et al. Enantioselective pharmacokinetics of homochlorcyclizine II: disposition and metabolism of (+)-, (−)- and racemic homochlorcyclizine after oral administration to man. Eur J Clin Pharmacol 43, 533–538 (1992). https://doi.org/10.1007/BF02285097
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02285097